Lung nodules grow for fundamentally different reasons depending on whether they are benign or malignant, and the speed and pattern of that growth is one of the strongest clues doctors use to tell the two apart. Malignant nodules are fueled by genetic mutations that hijack normal cell division, blood vessel recruitment, and immune evasion. Benign nodules grow through entirely different mechanisms: infection, inflammation, or the slow expansion of disorganized but non-cancerous tissue. The trouble is that these categories do not always behave the way textbooks predict, and a nodule’s growth rate alone cannot definitively settle the question.
How Malignant Nodules Grow
Cancer cells in the lung grow because their DNA has accumulated mutations that override the normal brakes on cell division. Two of the most studied driver mutations in lung adenocarcinoma are in the EGFR and KRAS genes, both of which promote uncontrolled cell division and help cancer cells invade surrounding tissue.1PubMed Central. Clinical impact of EGFR and KRAS mutations in surgically treated unifocal and multifocal lung adenocarcinoma A study of subsolid nodules (the hazy, ground-glass type often seen on CT) found that EGFR mutations were present in about 73% of nodules that grew over time, compared to only 10% of nodules that stayed the same size.2PubMed Central. Correlation analysis between growth heterogeneity and genetic mutations in resected subsolid lung adenocarcinoma based on long-term computed tomography (CT) follow-up That is a striking difference, and it suggests that the presence of certain mutations is a powerful engine behind whether a nodule progresses or sits still.
Beyond the mutations themselves, malignant nodules recruit their own blood supply through a process called angiogenesis. Tumors cannot grow beyond a tiny size without new blood vessels to deliver oxygen and nutrients, so cancer cells release chemical signals that stimulate vessel formation. This blood vessel recruitment also helps tumor cells invade surrounding tissue and eventually spread to distant sites.3PubMed Central. Angiogenesis in Lung Cancer: Understanding the Roles of Growth Factors The tumor’s local environment plays a role too. Certain immune cells that accumulate around early-stage lung adenocarcinomas can actually promote tumor blood vessel growth and metastasis rather than suppressing it.4PubMed Central. Senescent SPP1(+) macrophages remodel the tumor microenvironment and promote the progression of early-stage lung adenocarcinoma featured with mixed ground glass nodule
Environmental exposures also set the stage. Tobacco smoke remains the dominant risk factor, but occupational and environmental carcinogens like asbestos, radon, and silica are well-recognized contributors to non-small-cell lung cancer.5PubMed. Does occupational exposure affect the surgical management of patients with non-small cell lung cancer? A single-center retrospective experience These exposures cause the DNA damage that accumulates into the driver mutations described above, so they are upstream causes rather than direct growth signals. But they explain why some people develop malignant nodules and others do not.
How Benign Nodules Grow
Benign nodules have no cancerous machinery, so their growth comes from other biological processes. The causes fall into a few broad categories: infections, non-infectious inflammation, and benign tumors.
Fungal infections are a common culprit, especially in certain geographic regions or in people with weakened immune systems. Fungal nodules tend to appear in younger patients who are more likely to be nonsmokers and immunocompromised. On imaging, they often show distinctive features like a halo sign, an air crescent sign, or small satellite lesions clustered around the main nodule.6Dove Medical Press. Clinical and Computed Tomography Characteristics of Solitary Pulmonary Nodules Caused by Fungi: A Comparative Study These nodules grow because the body’s immune response walls off the infection with layers of inflammatory tissue, forming a granuloma that can slowly enlarge. Bacterial infections, tuberculosis, and parasites can produce similar nodules.
Autoimmune and inflammatory conditions are another source. Rheumatoid arthritis, for instance, can produce rheumatoid pulmonary nodules that grow as the underlying disease flares. These fall under the umbrella of non-infectious inflammatory lesions.7Journal of Pulmonary Medicine & Respiratory Research. Pulmonary Nodules In Patients With Chronic Rheumatoid Arthritis: An Up-To-Date Review
Then there are benign tumors like hamartomas, the most common benign lung tumor. Hamartomas are masses of disorganized cartilage, fat, and connective tissue. They usually grow very slowly, but exceptions exist. One case report documented a hamartoma that grew from 12 by 15 millimeters to 15 by 20 millimeters in just five months, giving it a doubling time of roughly 132 days, fast enough that cancer was strongly suspected until surgery revealed it was harmless.8PubMed Central. A case of pulmonary hamartoma showing rapid growth Cases like this are a reminder that growth speed alone cannot always distinguish benign from malignant.
Growth Speed as a Diagnostic Clue
Despite the overlap, the rate at which a nodule doubles in volume is one of the most reliable tools for assessing risk. Doctors measure this as the volume doubling time, or VDT. In screening studies, malignant solid nodules had a median VDT of about 204 days, while benign growing nodules had a median VDT of roughly 386 days. About 92% of malignant nodules doubled in volume in under 400 days, compared to 58% of benign ones.9PubMed Central. Volume Doubling Times of Benign and Malignant Nodules in Lung Cancer Screening
The clinical takeaway is that a nodule doubling in under 400 days raises suspicion, but it does not guarantee cancer. And a slowly growing nodule is not automatically safe. VDT is most useful when combined with other information, not treated as a standalone verdict. The updated Fleischner Society guidelines, which most radiologists follow for managing incidentally discovered nodules, emphasize this point: growth rate matters, but so do the nodule’s shape, density, internal features, and the patient’s individual risk factors.10PubMed. Updated Fleischner Society Guidelines for Managing Incidental Pulmonary Nodules: Common Questions and Challenging Scenarios
The Slow-Motion Path From Hazy to Solid
Some lung nodules begin as faint, hazy patches on CT scans known as ground-glass opacities. These represent early-stage changes in the lung tissue and are increasingly detected because modern CT scanners are so sensitive. The clinical challenge is that many of these are precancerous or early cancerous lesions that evolve over years or even decades.
Studies following ground-glass nodules over time show that about three-quarters eventually increase in size, and a smaller proportion develop a solid component within them. A greater solid component corresponds with a greater likelihood of invasive cancer.11Journal of Surgery. Multistep Progression from Atypical Adenomatous Hyperplasia to Lung Adenocarcinoma: Clinico-Pathologic, Epigenetic and Genetic Aspects This progression from pure ground-glass to part-solid to predominantly solid reflects a real biological transformation: the tissue is going from a pre-invasive state to full-blown invasive adenocarcinoma. The EGFR mutations discussed earlier are heavily involved at every stage, with invasive lesions carrying these mutations at a much higher rate than their pre-invasive counterparts.2PubMed Central. Correlation analysis between growth heterogeneity and genetic mutations in resected subsolid lung adenocarcinoma based on long-term computed tomography (CT) follow-up
This slow evolution is actually good news in a way. It means there is often a long window during which these nodules can be caught and treated before they become dangerous. But it also means patients can spend years in surveillance, which carries its own costs.
What a Nodule Looks Like on Imaging
Beyond size and growth rate, radiologists pay close attention to shape and internal features. Malignant nodules tend to have spiculated (spiky) edges, lobulated contours, pleural indentation where they tug on the lung lining, and signs of internal air trapping like bubble-like lucencies or irregular air passages running through them.12PubMed Central. Evaluation of the solitary pulmonary nodule: size matters, but do not ignore the power of morphology The presence of nearby blood vessels converging toward the nodule, known as the vascular cluster sign, along with distortion of the airway architecture, are also significant predictors of malignancy.13PubMed. Creation of nomograms that combine clinical, CT, and radiographic features to separate benign from malignant diseases using spiculation or (and) lobulation signs
Benign nodules, by contrast, are more likely to be smooth, round, and well-defined. Fungal nodules, as noted earlier, often have distinctive halo or crescent signs and satellite lesions nearby that cancer rarely produces. A popcorn pattern of calcification is a classic hamartoma clue. None of these individual features is a guarantee on its own, but taken together with growth pattern and patient history, they build a picture that guides the next step.
PET Scans and Their Limitations
When a CT scan is ambiguous, doctors often turn to PET scanning, which measures how actively cells are consuming sugar. Cancer cells are metabolically hungry, so they light up brightly. A common threshold is a standardized uptake value of 2.5 or higher, which is traditionally used as a cutoff suggesting malignancy.14PubMed Central. Relation between nodule size and 18F-FDG-PET SUV for malignant and benign pulmonary nodules
The problem is that this cutoff works much better for larger nodules. For nodules a centimeter or smaller, the test has little value because even cancerous ones may not consume enough sugar to cross the threshold. Some infections and inflammatory conditions also light up on PET, producing false positives. Using dual-time-point imaging, where the scan is repeated after a delay, can help: malignant nodules tend to show increasing sugar uptake over time, while benign ones plateau or decrease.15PubMed Central. Clinical Impact of FDG PET/CT in Pulmonary Nodule Characterization: Current Perspectives on Dual-Time-Point Imaging and Semi-Quantitative Imaging Metrics For nodules with low uptake overall, lowering the threshold to around 1.6 and using the change over time can improve accuracy, correctly classifying about 84% of otherwise ambiguous lesions.16Journal of Nuclear Medicine. Accuracy of PET for Diagnosis of Solid Pulmonary Lesions with 18F-FDG Uptake Below the Standardized Uptake Value of 2.5
Getting a Tissue Sample
When imaging cannot settle the question, the next step is obtaining tissue for examination under a microscope. The two main approaches are needle biopsy through the chest wall and bronchoscopy through the airways. Each has trade-offs.
CT-guided needle biopsy through the chest wall has strong sensitivity, reaching about 89% even for nodules smaller than one centimeter and nearly perfect specificity for confirming cancer. The major drawback is that roughly one in five patients develops a pneumothorax (air leak around the lung), and about half of those need a chest tube to re-expand the lung.17PubMed Central. The Role of Bronchoscopy in the Management of Lung Nodules. Is it too Early to Retire Transthoracic Needle Aspiration? A negative needle biopsy also cannot fully rule out cancer because the needle may miss the malignant portion of the nodule, so further workup is usually needed if the result comes back benign.
Robotic-assisted bronchoscopy, a newer approach, reaches peripheral nodules through the airways using real-time navigation. Its diagnostic yield is comparable to needle biopsy, but the rate of pneumothorax requiring treatment is roughly 75% lower.18PubMed Central. Robotic-assisted transbronchial biopsy versus computed tomography–guided transthoracic needle biopsy for peripheral pulmonary lesions: a systematic review and meta-analysis of direct comparative studies A systematic review of multiple bronchoscopic technologies found that overall diagnostic yield across methods is around 78%, with the safest techniques having pneumothorax rates under 1%.19European Respiratory Review. Diagnostic yield and safety of diagnostic techniques for pulmonary lesions: systematic review, meta-analysis and network meta-analysis The technology is evolving rapidly, and for patients who are poor candidates for a chest-wall needle or who have centrally located nodules, bronchoscopy is increasingly the preferred route.
Treating Suspicious Nodules Without Surgery
Not every suspicious nodule ends up in the operating room. Stereotactic body radiation therapy, or SBRT, delivers highly focused radiation beams to a small lung target over a few sessions. It is used for patients who cannot tolerate surgery or who have early-stage cancers that are small and localized. A study of patients treated with SBRT for suspicious nodules found two-year local control rates above 94%, with complete disappearance of the nodule on imaging in about half of treated lesions by the two-year mark.20PubMed Central. The Effectiveness of SBRT for Solitary or Synchronous Multiple Pulmonary Nodules Suspicious of Early-Stage Lung Cancer Without Pathological Confirmation Tumor response tends to improve over time: many nodules initially just stabilize and then gradually shrink over the following months.
Artificial Intelligence and Predicting Growth
One of the most active areas of research is using artificial intelligence to predict whether a nodule will grow based on a single CT scan. Traditional monitoring requires waiting months between scans to measure change, but AI models trained on large datasets can analyze subtle patterns in the scan image itself. These models combine radiomics (extracting hundreds of quantitative features from the image) with deep learning and clinical data like age to estimate growth risk.
A fusion model combining radiomics and deep learning achieved an area under the curve of 0.90 for predicting nodule growth, outperforming either approach used alone.21PubMed Central. Predicting pulmonary nodule growth from a single time point: a fusion model of radiomics and deep learning to optimize follow-up strategies Another study found that a model combining age with radiomic features reached an accuracy of 84% on validation data for predicting whether a nodule would grow over the following year.22PubMed Central. Prediction of single pulmonary nodule growth by CT radiomics and clinical features – a one-year follow-up study These tools detect nodule growth earlier and more consistently than simple diameter measurements and do a better job distinguishing fast-growing from indolent nodules.23PubMed Central. Narrative review: the research advances of artificial intelligence in the prediction of pulmonary nodule growth
These AI tools are not replacing doctors yet. Most are still being validated, and they work best as a second opinion layered on top of clinical judgment. But they have the potential to spare low-risk patients from unnecessary repeat scans while flagging high-risk nodules for earlier intervention.
The Psychological Weight of Waiting
For the person living with a lung nodule, the biological distinction between benign and malignant can feel abstract when the practical reality is months or years of surveillance scans. Research consistently shows that learning about a lung nodule causes real psychological distress. Patients commonly assume the nodule is cancerous, fear surgery, and endure negative psychological effects throughout the waiting period.24Respiratory Medicine and Research. Pulmonary nodules and the psychological harm they can cause: A scoping review Studies find that the prevalence of at least mild nodule-specific distress ranges from about 24% to 57%, with anxiety affecting anywhere from 18% to 62% of patients and depression affecting 15% to 27%.
Perhaps most striking, anxiety persisted or worsened in about 27% of patients under surveillance even though their nodules were clinically classified as low-risk. This mirrors findings from large screening trials, where persistent distress occurred even after reassuring imaging results.25PubMed Central. Psychological distress in patients with detected pulmonary nodules from lung cancer screening Patients whose nodules were surgically removed tended to feel psychological relief from the resolution of uncertainty, while those on prolonged surveillance continued to experience anxiety, especially when imaging showed ambiguous features like mixed ground-glass patterns.26PubMed Central. Patients’ experiences of, and psychological responses to, surveillance for pulmonary nodules detected through lung cancer screening
This is worth knowing because it reframes the nodule question as more than a purely medical one. The decision about how aggressively to investigate or monitor a nodule involves weighing cancer risk against procedure risk, but it also involves the real toll of living with uncertainty. Patients who understand that the overwhelming majority of detected nodules turn out to be benign, and who receive clear communication about what their specific features and growth pattern mean, tend to cope better with that uncertainty. If you have been told you have a lung nodule and are struggling with the waiting, that struggle is normal and well-documented, and raising it with your care team is worth doing.